← Eichor
Study identifier: NCT07316504 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Optimal Strategy to Correct Stent underexpAnsion in Resistant Lesions

Condition: Coronary Angioplasty · Restenosis · Lithotripsy  ·  Sponsor: University Hospital, Clermont-Ferrand

PhaseNA
Planned participants80
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

Percutaneous coronary intervention (PCI) for in-stent restenosis (ISR) accounts for 5-10% of PCI. ISR may be linked to mechanical complications mainly under-expansion (UE), neointimal hyperplasia and/or neoatherosclerosis. International guidelines recommends non-compliant and very-high-pressure balloons, which lead to sub-optimal angiographic and clinical results. Recently, observational studies have suggested the feasibility and safety of intravascular lithotripsy (IVL) in UE treatment. There are no prospective randomised controlled studies comparing intravascular lithotripsy with balloons in ISR with UE.

This description comes directly from the study's public registry record.

Talk to the study team

Lise Laclautre, Pharm.D  ·  +33473754963  ·  promo_interne_drci@chu-clermontferrand.Fr

Always discuss trial participation with your own doctor first.

Locations (2)

Clermont Ferrand HospitalClermont-Ferrand, Auvergne, FranceRecruiting
CHU de Clermont-FerrandClermont-Ferrand, FranceNot Yet Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07316504